E-LIB Suche - Ergebnisse für: Cortes, A.

1

Magma recharge in persistently active basaltic–andesite sys..:

Cortés, J. A. ; Gertisser, R. ; Calder, E. S.
International Journal of Earth Sciences. 113 (2024) 5 - p. 1145-1163 , 2024

Link: https://doi.org/10.1007/..

2

IMpassion132 double-blind randomised phase III trial of che..:

Dent, R. ; André, F. ; Gonçalves, A....
Annals of Oncology. 35 (2024) 7 - p. 630-642 , 2024

Link: https://doi.org/10.1016/..

3

Gut microbiota and immune profiling of microbiota-humanised..:

Stark, K. A. ; Rinaldi, G. ; Costain, A....
Animal Microbiome. 6 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

4

74P Assessing the implementation of the HER2DX genomic test..:

Cejalvo, J.M. ; Soberino, J. ; Ciruelos, E.M....
ESMO Open. 9 (2024) - p. 103080 , 2024

Link: https://doi.org/10.1016/..

5

Prognostic value of HER2DX in early-stage HER2-positive bre..:

Villacampa, G. ; Pascual, T. ; Brasó-Maristany, F....
ESMO Open. 9 (2024) 3 - p. 102388 , 2024

Link: https://doi.org/10.1016/..

6

133P Molecular profile and actionability of sarcomas with n..:

Zugman, M. ; Fernandes, M. ; de Lima, L....
ESMO Open. 9 (2024) - p. 102522 , 2024

Link: https://doi.org/10.1016/..

7

Development and validation of a model to predict ceiling of..:

Pallarès, N ; Inouzhe, H ; Straw, S...
BMC Palliative Care. 23 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

8

Enhancing efficiency and sustainability of digital light pr..:

Cortés, A. ; Bañón-Veracruz, M. ; Jiménez-Suárez, A....
Journal of Materials Research and Technology. 29 (2024) - p. 3237-3248 , 2024

Link: https://doi.org/10.1016/..

9

Early prediction of endocrine responsiveness in ER+/HER2-ne..:

Gennari, A. ; Brain, E. ; De Censi, A....
Annals of Oncology. 35 (2024) 6 - p. 549-558 , 2024

Link: https://doi.org/10.1016/..

10

189P The impact of high body mass index (BMI) on the safety..:

Estevez, L. García ; Bardia, A. ; Rugo, H.S....
ESMO Open. 9 (2024) - p. 103211 , 2024

Link: https://doi.org/10.1016/..

11

183MO Capivasertib and fulvestrant (F) for patients (pts) w..:

Rugo, H.S. ; Oliveira, M. ; Howell, S.J....
ESMO Open. 9 (2024) - p. 103205 , 2024

Link: https://doi.org/10.1016/..

12

Neoadjuvant pembrolizumab or placebo + chemotherapy, follow..:

Cardoso, F. ; O'Shaughnessy, J. ; McArthur, H....
European Journal of Cancer. 200 (2024) - p. 113608 , 2024

Link: https://doi.org/10.1016/..

13

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2..:

Hurvitz, S.A. ; Kim, S.-B. ; Chung, W.-P....
ESMO Open. 9 (2024) 5 - p. 102924 , 2024

Link: https://doi.org/10.1016/..

14

1MO HER2DX assay and survival outcomes: An individual-patie..:

Javierre, G. Villacampa ; Cortés, J. ; García, J.M. Pérez...
ESMO Open. 9 (2024) - p. 103011 , 2024

Link: https://doi.org/10.1016/..

15

Insights into HER2-Low Status and the Breast Cancer Immune ..:

Di Cosimo, S. ; Pizzamiglio, S. ; Ciniselli, C.M....
European Journal of Cancer. 200 (2024) - p. 113864 , 2024

Link: https://doi.org/10.1016/..